Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor.

@article{Dorr1993ClinicalPO,
  title={Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor.},
  author={Robert T. Dorr},
  journal={Clinical therapeutics},
  year={1993},
  volume={15 1},
  pages={19-29; discussion 18}
}
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) can be expressed in yeast, bacteria, or mammalian cells. Expression in each system results in a protein that differs, to a varying extent, from native GM-CSF. Like the native protein, yeast-expressed GM-CSF is glycosylated and has 127 amino acids, but differs from native GM-CSF in molecular mass and in the substitution of leucine for proline at position 23. GM-CSF expressed in Escherichia coli bacteria is not… CONTINUE READING
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…